Anurag Kumar

Morepen is a market leader in glucometers, having installed over 12 million units to date and sold nearly 1.6 million blood glucose strips, driven by an aggressive market expansion strategy into tier-2 and tier-3 cities. As a leading manufacturer of BP monitors, the company has shown impressive growth in the Point of Care (POC) diagnostics segment. In the API business, Morepen holds a leadership position in the export of six key API products: Loratadine, Montelukast, Desloratadine, Atorvastatin, and Fexofenadine, catering to numerous international markets and exporting to over 80 countries. Approximately 68% of Morepen's API products are exported, highlighting its extensive global reach. The company has demonstrated consistent growth in both its top and bottom lines through strategic investments and market expansions. Morepen maintains a debt-free status with robust financials and a negligible interest burden, underscoring its financial stability. Founded in 1984, Morepen Laboratories Limited (www.morepen.com) has established itself as a prominent leader in the pharmaceutical industry, renowned for its high-quality products and innovative solutions. The company offers a diverse range of products, including active pharmaceutical ingredients, diagnostics, and over-the-counter items. Morepen is dedicated to enhancing global health through its advanced research and development efforts.